PROVECTUS BIOPHARMACEUTICALS, INC.·4

May 9, 4:50 PM ET

Morris Jeffrey Allen 4

4 · PROVECTUS BIOPHARMACEUTICALS, INC. · Filed May 9, 2023

Insider Transaction Report

Form 4
Period: 2023-05-08
Transactions
  • Conversion

    Series D-1 Convertible Preferred Stock

    2023-05-08$2.86/sh+188,757$540,2233,995,747 total
Holdings
  • Common Stock

    12,000,000
  • Common Stock

    (indirect: By IRA)
    6,500,000
Footnotes (3)
  • [F1]The reporting person has sole voting and dispositive power over 12,000,000 shares of Common Stock.
  • [F2]The reporting person has sole voting and dispositive power over 6,500,000 shares of Common Stock owned through an IRA retirement plan.
  • [F3]The reporting person has sole voting and dispositive power over 3,995,747 shares of Series D-1 Convertible Preferred Stock, convertible into 39,957,470 shares of Common Stock.

Documents

1 file
  • 4
    ownership.xmlPrimary